Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives

News

 24th November 2010
Bio Nano Consulting

Bio Nano Consulting completes public funding phase

Fully self-financed, revenue-driven company

BNC opens new London offices as part of expansion plan

Bio Nano Consulting (BNC), specialists in bio and nanotechnology partnerships between the academic and industrial sectors, announces the completion of its publicly funded phase of corporate development. At the same time, to mark the company’s transition to a self-supporting and revenue-funded organisation, BNC has unveiled new expanded London offices, acquired to meet the increasing demand for its services and specialist expertise.

BNC was formed in 2007 as the UK’s Micro and Nanotechnology Centre focused on bionanotechnology, with funding from the Technology Strategy Board (TSB) and the London Development Agency (LDA). The funding provided open access to facilities in BNC’s partner institutions, which is to continue.

Since the company’s launch, Bio Nano Consulting has completed 22 projects for 16 life science and high-technology sector companies. Furthermore, the company already has a further 10 projects actively in progress. BNC is now partnered with three leading academic institutions, namely Imperial College London, University College London and the School of Pharmacy, University of London. The formation of a fourth, internationally focused partnership is expected to be announced this year.

The company’s new London office premises are located in Central London.

Commenting on BNC’s new status as a fully self financed and revenues supporting organisation, CEO, Dr David Sarphie, commented: “We are pleased to have completed the first phase of our business plan and to have exceeded our growth projections. We have made effective use of TSB and LDA publicly funded resources to help UK and international clients adopt nanotechnology and also to drive the success of Bio Nano Consulting, enabling the company to emerge as a fully self-financed, revenue-driven enterprise. We predict continued revenue growth as we confidently embark on the planned second phase in our company’s development.”

He added; “We look forward to servicing the expanding stream of project based clients in international markets, all of whom will continue to benefit from our unique business model that combines strong project management expertise with access to scientists in world leading academic institutions.”

-ENDS-

Editors’ notes

About Bio Nano Consulting Bio Nano Consulting is a joint venture of Imperial College London and University College London that specialises in delivering innovative solutions to industry across the life sciences and technology sectors. We are the first consultancy in Europe to focus on the intersection between bio and nanotechnology, providing product development and strategic consultancy, project management and access to state of the art instrumentation and world-leading researchers.

Through its partner organisations of UCL, Imperial College, the National Physical Laboratory, and now the School of Pharmacy, University of London, BNC offers services to the biomedical, healthcare and technology industries.

For more information, please contact Tristan Jervis or Alex Heeley on 00 44 207 861 3838 or e-mail t.jervis@defacto.com.


 

Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |